| RARX - Ra Pharmaceuticals Inc (Healthcare: Biotechnology) | Projected Earnings Date: 2020-09-05 (Delayed quote data ) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis and lupus nephritis. Geographically business of the firm can be seen amplifying in the United States, Europe and even at international level. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |